Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed Kaposi's sarcoma (KS) involving the following:
• * Skin
• * Lymph nodes (palpable disease only)
• * Oral cavity
• Must have ≥ 5 measurable, previously nonirradiated, cutaneous lesions that can be used as indicator lesions
• Must have 2 lesions ≥ 5 x 5 mm that are accessible for 4 mm punch biopsy
• Serologically confirmed HIV positivity
• Concurrent antiretroviral therapy required, except for patients who have exhausted all available treatment options
• * Must be on a stable dose for ≥ 4 weeks
• PATIENT CHARACTERISTICS:
• Life expectancy ≥ 3 months
• No other neoplasia requiring cytotoxic therapy
• Not pregnant or nursing
• Fertile patients must use effective barrier contraception during and for 3 months after completion of study treatment
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics
• No prior anthracycline therapy
• At least 4 weeks since prior antineoplastic treatment for KS, including any of the following:
• * Chemotherapy (6 weeks for nitrosoureas or mitomycin C)
• * Radiotherapy
• * Local therapy
• * Biological therapy
• * Investigational therapy
• At least 60 days since prior local therapy of any KS indicator lesion unless lesion has clearly progressed since treatment
• No other concurrent investigational drugs, cytotoxic chemotherapy, or KS-specific treatment